Juvenile idiopathic arthritis.


Journal Article (Review)

A significant amount of work has been performed over the past 2 years further defining the pathophysiology of juvenile idiopathic arthritis (JIA). The development of the biologic agent etanercept represents successful translational research. This genetically engineered fusion protein targets tumor necrosis factor, binding and inactivating this important component of inflammation. This advance has been accompanied by refinements in classification, as well as further elucidation of the natural disease course of JIA. Recent work continues to demonstrate the widespread nature of JIA, as well as its severity in adulthood.

Full Text

Duke Authors

Cited Authors

  • Kulas, DT; Schanberg, L

Published Date

  • September 2001

Published In

Volume / Issue

  • 13 / 5

Start / End Page

  • 392 - 398

PubMed ID

  • 11604594

Pubmed Central ID

  • 11604594

International Standard Serial Number (ISSN)

  • 1040-8711

Digital Object Identifier (DOI)

  • 10.1097/00002281-200109000-00009


  • eng

Conference Location

  • United States